Xilio Therapeutics Inc (XLO)
1.08
-0.04
(-3.57%)
USD |
NASDAQ |
May 16, 16:00
1.06
-0.02
(-1.85%)
After-Hours: 20:00
Xilio Therapeutics Cash from Operations (TTM): -53.87M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -53.87M |
| December 31, 2023 | -68.62M |
| September 30, 2023 | -73.42M |
| June 30, 2023 | -79.96M |
| March 31, 2023 | -80.14M |
| Date | Value |
|---|---|
| December 31, 2022 | -75.72M |
| September 30, 2022 | -74.66M |
| June 30, 2022 | -75.47M |
| March 31, 2022 | -78.85M |
| December 31, 2021 | -80.75M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-80.75M
Minimum
Dec 2021
-53.87M
Maximum
Mar 2024
-74.15M
Average
-75.60M
Median
Cash from Operations (TTM) Benchmarks
| Gilead Sciences Inc | 8.481B |
| FibroGen Inc | -272.72M |
| Avalo Therapeutics Inc | -30.68M |
| IGM Biosciences Inc | -183.65M |
| AEON Biopharma Inc | -- |